Noninvasive Test Helps Identify Cause of Specific Kidney Disease
|
By LabMedica International staff writers Posted on 02 Jul 2014 |

Image: Histopathology of a kidney showing membranous glomerulonephritis (Photo courtesy of University of Utah).
The first test that can help determine a specific type of kidney disease, called membranous glomerulonephritis (MGN) has been authorized for marketing.
Membranous glomerulonephritis (MGN) is a chronic kidney disease that causes damage to the glomeruli, which are the cluster of tiny tufts of capillary blood vessels in the kidney that filter the blood and begin the process to remove waste and excess fluid from the blood.
The US Food and Drug Administration (Silver Springs, MD, USA) reviewed a clinical study of 560 blood samples of which 275 samples were obtained from patients with presumed primary MGN (pMGN), while 285 samples were obtained from patients diagnosed with other kidney diseases including secondary MGN (sMGM) and autoimmune diseases, not including pMGN, that can damage the kidney, like lupus erythematosus.
The EUROIMMUN Anti- PLA2R IFA blood test (Euroimmun US Inc.; Morris Plains, NJ, USA) detects if a patient has an antibody, a protein molecule the body’s immune system produces, that is specific to pMGN. The test was able to detect pMGN in 77% of the presumed pMGN samples, and gave a false positive result in less than 1% of the other disease samples. Notably, the test was helpful in distinguishing between pMGN from sMGN in most of the patients. The test should not be used alone to diagnose pMGN. Additional information, including patient symptoms and other laboratory tests, should always be considered when making a diagnosis of pMGN. A biopsy of the kidney is needed to confirm the diagnosis of pMGN. A negative result from the test does not rule out a diagnosis of pMGN.
Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics at the FDA, said, “Treatment of MGN depends on the underlying cause of the disease. This test can help patients get a timely diagnosis for their MGN and aid with earlier treatment.” The FDA reviewed the EUROIMMUN Anti- PLA2R IFA blood test through its de novo classification process, a regulatory pathway for some novel low- to moderate-risk medical devices that are first-of-a-kind. The test should not be used to monitor the stage of disease or the response to treatment.
Symptoms of MGN include swelling, high cholesterol, high blood pressure and increased predisposition to blood clots. Over time, usually 10 to 20 years, some people with MGN proceed to kidney failure and require a kidney transplant. MGN affects mostly adult, Caucasian men. About 85% of MGN cases are caused by the body’s immune system mistakenly attacking healthy kidney tissue, which is one of the leading causes of kidney disease in adults.
Related Links:
US Food and Drug Administration
Euroimmun US Inc.
Membranous glomerulonephritis (MGN) is a chronic kidney disease that causes damage to the glomeruli, which are the cluster of tiny tufts of capillary blood vessels in the kidney that filter the blood and begin the process to remove waste and excess fluid from the blood.
The US Food and Drug Administration (Silver Springs, MD, USA) reviewed a clinical study of 560 blood samples of which 275 samples were obtained from patients with presumed primary MGN (pMGN), while 285 samples were obtained from patients diagnosed with other kidney diseases including secondary MGN (sMGM) and autoimmune diseases, not including pMGN, that can damage the kidney, like lupus erythematosus.
The EUROIMMUN Anti- PLA2R IFA blood test (Euroimmun US Inc.; Morris Plains, NJ, USA) detects if a patient has an antibody, a protein molecule the body’s immune system produces, that is specific to pMGN. The test was able to detect pMGN in 77% of the presumed pMGN samples, and gave a false positive result in less than 1% of the other disease samples. Notably, the test was helpful in distinguishing between pMGN from sMGN in most of the patients. The test should not be used alone to diagnose pMGN. Additional information, including patient symptoms and other laboratory tests, should always be considered when making a diagnosis of pMGN. A biopsy of the kidney is needed to confirm the diagnosis of pMGN. A negative result from the test does not rule out a diagnosis of pMGN.
Alberto Gutierrez, PhD, director of the Office of In Vitro Diagnostics at the FDA, said, “Treatment of MGN depends on the underlying cause of the disease. This test can help patients get a timely diagnosis for their MGN and aid with earlier treatment.” The FDA reviewed the EUROIMMUN Anti- PLA2R IFA blood test through its de novo classification process, a regulatory pathway for some novel low- to moderate-risk medical devices that are first-of-a-kind. The test should not be used to monitor the stage of disease or the response to treatment.
Symptoms of MGN include swelling, high cholesterol, high blood pressure and increased predisposition to blood clots. Over time, usually 10 to 20 years, some people with MGN proceed to kidney failure and require a kidney transplant. MGN affects mostly adult, Caucasian men. About 85% of MGN cases are caused by the body’s immune system mistakenly attacking healthy kidney tissue, which is one of the leading causes of kidney disease in adults.
Related Links:
US Food and Drug Administration
Euroimmun US Inc.
Latest Pathology News
- Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
- AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
- New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
- Breakthrough-Designated Cytology Test Supports Oral Cancer Risk Assessment
- Review Highlights Progress and Validation Needs for AI in Digital Pathology
- Roche Launches Automated Test to Support Mesothelioma Differential Diagnosis
- AI Pathology Approach Closely Aligns With Breast Cancer Genomic Risk Classification
- Digital Pathology Test Stratifies Recurrence Risk in Early Breast Cancer
- AI Pathology Tool Predicts DNA Repair Deficiency in High-Grade Serous Ovarian Cancer
- AI Tissue Analysis May Help Identify Missed Precancerous Colon Polyps
- AI Pre-Screening Helps Identify Lung Cancer Cases for Additional Biomarker Testing
- AI Pathology Platform Targets Workflow Delays and Molecular Test Failures
- Updated Digital Pathology Platform Expands AI Integration for Cancer Diagnosis
- Molecular Testing Refines Barrett’s Esophagus Progression Risk Beyond Biopsy Findings
- AI Histopathology Tool Distinguishes Ewing Sarcoma for Diagnosis
- Rapid Mass Spectrometry Test May Aid Glioma Margin Decisions
Channels
Clinical Chemistry
view channelAI and Nanotechnology Enable Five-Minute Urine Drug Screening
Rapid screening for illicit drugs remains challenging when testing must be performed at the point of care. Laboratory methods provide accurate results but require sample preparation and specialized equipment,... Read more
Study Questions Uniform Stool-Test Cutoff Across Age Groups
Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read moreMolecular Diagnostics
view channel
Blood RNA Patterns Linked to CAR T-Cell Response and Survival in Lymphoma
Anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, which involves engineering a patient’s own immune cells to recognize and attack cancer cells, has transformed treatment for large B-cell lymphoma,... Read moreGenome Sequencing Provides Clues to Unexplained Recurrent Miscarriages
Recurrent pregnancy loss, defined as two or more miscarriages, affects about 5% of couples. In many cases, routine evaluation does not identify a cause, particularly when pregnancies have a normal chromosome... Read moreHematology
view channel
Werfen Gains FDA Clearance for ROTEM sigma Cartridge Use in Trauma
Traumatic injuries account for approximately 10% of deaths worldwide, with uncontrolled bleeding remaining a leading cause of potentially preventable trauma-related death. Trauma-induced coagulopathy further... Read more
Serial Blood Samples Reveal Leukemia’s Evolution Decades Before Diagnosis
Acute myeloid leukemia (AML) is an aggressive blood cancer affecting approximately 2,700 people in the U.K. annually, with only about one in six patients surviving five years after diagnosis.... Read moreMicrobiology
view channel
WHO Survey Reveals Gaps in Antimicrobial Resistance Testing and Response
Antimicrobial resistance (AMR) remains a major challenge for health systems, limiting effective treatment options for drug-resistant infections. These infections caused more than 1 million deaths and contributed... Read more
Direct-From-Specimen Pneumonia Test Detects Pathogens and Resistance in Hours
Pneumonia is a leading cause of sepsis and is associated with high mortality. Conventional culture-based pathogen identification and antimicrobial susceptibility testing can take two to four days, delaying... Read morePathology
view channel
Researchers Evaluate Automated Tissue Analysis Across Four Cancer Types
Histopathology image analysis plays a central role in cancer diagnosis, but tumor tissue can vary considerably across different regions of the same specimen. Pathologists examine cellular morphology, nuclear... Read more
AI Prostate Cancer Test Added to NCCN Guidelines for Post-Surgery Recurrence
Following radical prostatectomy, an estimated 20% to 40% of prostate cancer patients develop biochemical recurrence, marked by rising prostate-specific antigen levels that may indicate cancer recurrence.... Read more
New Training Approach Helps AI Distinguish Neighboring Cells in Tissue
Artificial intelligence (AI) can assist with identifying cells in digital pathology images, but densely packed tissue remains difficult to analyze. Neighboring cells may be merged, counted twice, or missed,... Read more
Review Highlights Progress and Validation Needs for AI in Digital Pathology
Pathology remains the gold standard for disease diagnosis, but clinical laboratories face growing demands for faster, more reproducible diagnostic and prognostic workflows. Digital pathology based on whole-slide... Read moreTechnology
view channel
Experimental Blood Test Detects Markers of Three Cancers and Alzheimer’s Disease
Colorectal cancer, glioblastoma, pancreatic cancer, and Alzheimer’s disease are serious conditions in which earlier detection may improve clinical outcomes. Blood-based testing could help identify dis... Read more
New qPCR Master Mixes Offer Broad Compatibility for Routine Research
Quantitative PCR (qPCR) workflows require consistent reagent performance across instruments and assay formats. Laboratories must also manage costs without changing established protocols.... Read moreIndustry
view channel
Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil
Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more







